Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic Substances
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:VIVO
- CUSIP: 58958410
- Web: www.meridianbioscience.com
Capitalization:- Market Cap: $588.72 million
- Outstanding Shares: 42,202,000
Average Prices:- 50 Day Moving Avg: $14.10
- 200 Day Moving Avg: $14.96
- 52 Week Range: $10.75 - $20.68
P/E:- Trailing P/E Ratio: 19.53
- Foreward P/E Ratio: 19.93
- P/E Growth: 1.18
Sales & Book Value:- Annual Revenue: $198.6 million
- Price / Sales: 2.96
- Book Value: $4.05 per share
- Price / Book: 3.44
Dividend:- Annual Dividend: $0.50
- Dividend Yield: 3.7%
Profitability:- EBIDTA: $55.72 million
- Net Margins: 15.13%
- Return on Equity: 18.51%
- Return on Assets: 12.23%
Debt:- Debt-to-Equity Ratio: 0.32%
- Current Ratio: 5.99%
- Quick Ratio: 3.87%
Misc:- Average Volume: 332,642 shs.
- Beta: 1
- Short Ratio: 8.34
Frequently Asked Questions for Meridian Bioscience (NASDAQ:VIVO)
What is Meridian Bioscience's stock symbol?
Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."
How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?
Meridian Bioscience declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Monday, May 8th will be paid a dividend of $0.125 per share on Thursday, May 18th. This represents a $0.50 annualized dividend and a yield of 3.58%. The ex-dividend date is Thursday, May 4th. View Meridian Bioscience's Dividend History.
How were Meridian Bioscience's earnings last quarter?
Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its earnings results on Friday, April, 28th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.03. The business earned $54.13 million during the quarter, compared to analysts' expectations of $51.16 million. Meridian Bioscience had a net margin of 15.13% and a return on equity of 18.51%. The company's quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.24 EPS. View Meridian Bioscience's Earnings History.
What guidance has Meridian Bioscience issued on next quarter's earnings?
Meridian Bioscience updated its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $0.64-0.69 for the period, compared to the Thomson Reuters consensus estimate of $0.66. The company issued revenue guidance of $193-199 million, compared to the consensus revenue estimate of $194.58 million.
Where is Meridian Bioscience's stock going? Where will Meridian Bioscience's stock price be in 2017?
5 equities research analysts have issued twelve-month price targets for Meridian Bioscience's stock. Their predictions range from $9.00 to $19.00. On average, they expect Meridian Bioscience's stock price to reach $14.33 in the next year. View Analyst Ratings for Meridian Bioscience.
Who are some of Meridian Bioscience's key competitors?
Some companies that are related to Meridian Bioscience include Dermira (DERM), Novocure Ltd (NVCR), Eagle Pharmaceuticals (EGRX), Impax Laboratories (IPXL), Natus Medical (BABY), LHC Group (LHCG), Abaxis (ABAX), Medpace Holdings (MEDP), Surgery Partners (SGRY), Community Health Systems (CYH), Insmed Incorporated (INSM), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Acceleron Pharma (XLRN), Insys Therapeutics (INSY), Xencor (XNCR), Genomic Health (GHDX) and Cardiovascular Systems (CSII).
Who owns Meridian Bioscience stock?
Meridian Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (13.47%), Vanguard Group Inc. (8.73%), Renaissance Technologies LLC (4.71%), Dimensional Fund Advisors LP (3.38%), State Street Corp (2.95%) and BTIM Corp. (2.22%). Company insiders that own Meridian Bioscience stock include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.
Who sold Meridian Bioscience stock? Who is selling Meridian Bioscience stock?
Meridian Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Capstone Asset Management Co., Martingale Asset Management L P, Morgan Stanley, BTIM Corp., Schwab Charles Investment Management Inc., Menta Capital LLC and Nationwide Fund Advisors. Company insiders that have sold Meridian Bioscience stock in the last year include Richard Eberly and Vecheslav A Elagin. View Insider Buying and Selling for Meridian Bioscience.
Who bought Meridian Bioscience stock? Who is buying Meridian Bioscience stock?
Meridian Bioscience's stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Clark Estates Inc. NY, FMR LLC, State Street Corp, Quadrant Capital Group LLC, Dean Investment Associates LLC, Kennedy Capital Management Inc. and Renaissance Technologies LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.
How do I buy Meridian Bioscience stock?
Shares of Meridian Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Meridian Bioscience stock cost?
One share of Meridian Bioscience stock can currently be purchased for approximately $13.95.
Earnings History for Meridian Bioscience (NASDAQ:VIVO)Earnings History by Quarter for Meridian Bioscience (NASDAQ:VIVO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/28/2017 | Q2 2017 | $0.19 | $0.22 | $51.16 million | $54.13 million | View | N/A |  |
| 1/25/2017 | Q1 2017 | $0.20 | $0.15 | $51.15 million | $46.80 million | View | N/A | |
| 11/10/2016 | Q4 2016 | $0.14 | $0.14 | $47.17 million | $47.00 million | View | N/A | |
| 7/28/2016 | Q3 | $0.22 | $0.21 | $52.85 million | $50.70 million | View | N/A | |
| 4/28/2016 | Q2 | $0.24 | $0.24 | $52.10 million | $51.30 million | View | N/A | |
| 1/27/2016 | Q1 | $0.21 | $0.21 | $48.60 million | $47.20 million | View | N/A | |
| 11/5/2015 | Q4 | $0.21 | $0.20 | $45.70 million | $47.10 million | View | N/A | |
| 7/23/2015 | Q3 | $0.22 | $0.22 | $48.60 million | $48.20 million | View | N/A | |
| 4/23/2015 | Q115 | $0.24 | $0.24 | $50.50 million | $51.55 million | View | N/A | |
| 1/22/2015 | Q414 | $0.19 | $0.19 | $46.20 million | $48.00 million | View | N/A | |
| 11/6/2014 | Q4 | $0.22 | $0.20 | $48.94 million | $46.70 million | View | N/A | |
| 7/24/2014 | Q3 | $0.22 | $0.21 | $47.96 million | $47.20 million | View | N/A | |
| 4/24/2014 | Q214 | $0.27 | $0.24 | $52.18 million | $50.13 million | View | N/A | |
| 1/22/2014 | Q114 | $0.18 | $0.18 | $47.59 million | $44.80 million | View | N/A | |
| 11/7/2013 | Q313 | $0.23 | $0.22 | $49.24 million | $48.96 million | View | N/A | |
| 7/25/2013 | Q3 2013 | $0.21 | $0.24 | $47.00 million | $47.10 million | View | N/A | |
| 4/25/2013 | Q2 2013 | $0.24 | $0.24 | $49.66 million | $47.26 million | View | N/A | |
| 1/23/2013 | Q1 2013 | $0.19 | $0.20 | $44.34 million | $45.40 million | View | N/A | |
| 11/8/2012 | Q412 | $0.19 | $0.21 | $43.22 million | $43.70 million | View | N/A | |
| 7/26/2012 | | $0.22 | $0.21 | | | View | N/A | |
| 4/26/2012 | | $0.21 | $0.23 | | | View | N/A | |
| 1/25/2012 | | $0.19 | $0.17 | | | View | N/A | |
| 11/10/2011 | | $0.19 | $0.18 | | | View | N/A | |
| 7/21/2011 | | $0.21 | $0.17 | | | View | N/A | |
| 4/21/2011 | | $0.20 | $0.20 | | | View | N/A | |
| 1/20/2011 | | $0.19 | $0.15 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Meridian Bioscience (NASDAQ:VIVO)2017 EPS Consensus Estimate: $0.81
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.17 | $0.17 | $0.17 |
| Q2 2017 | 1 | $0.22 | $0.22 | $0.22 |
| Q3 2017 | 1 | $0.22 | $0.22 | $0.22 |
| Q4 2017 | 1 | $0.20 | $0.20 | $0.20 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Meridian Bioscience (NASDAQ:VIVO)| Most Recent Dividend: | 5/18/2017 |
| Annual Dividend: | $0.50 |
| Dividend Yield: | 3.58% |
| Payout Ratio: | 71.43% (Trailing 12 Months of Earnings)
73.53% (Based on This Year's Estimates)
71.43% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Meridian Bioscience (NASDAQ:VIVO)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 4/27/2017 | quarterly | $0.13 | 3.33% | 5/4/2017 | 5/8/2017 | 5/18/2017 |
| 1/25/2017 | quarterly | $0.13 | 3.91% | 2/2/2017 | 2/6/2017 | 2/16/2017 |
| 11/10/2016 | Quarterly | $0.20 | 4.6% | 11/17/2016 | 11/21/2016 | 12/1/2016 |
| 7/28/2016 | quarterly | $0.20 | 4.13% | 8/4/2016 | 8/8/2016 | 8/18/2016 |
| 4/28/2016 | quarterly | $0.20 | 4.19% | 5/5/2016 | 5/9/2016 | 5/19/2016 |
| 1/27/2016 | quarterly | $0.20 | 4.29% | 2/4/2016 | 2/8/2016 | 2/18/2016 |
| 11/5/2015 | quarterly | $0.20 | 3.89% | 11/12/2015 | 11/16/2015 | 11/27/2015 |
| 7/23/2015 | quarterly | $0.20 | 4.28% | 7/30/2015 | 8/3/2015 | 8/13/2015 |
| 4/23/2015 | quarterly | $0.20 | 4.18% | 4/30/2015 | 5/4/2015 | 5/14/2015 |
| 1/22/2015 | quarterly | $0.20 | 4.51% | 1/29/2015 | 2/2/2015 | 2/13/2015 |
| 11/6/2014 | quarterly | $0.20 | 4.75% | 11/13/2014 | 11/17/2014 | 11/28/2014 |
| 7/24/2014 | quarterly | $0.20 | 3.99% | 7/31/2014 | 8/4/2014 | 8/14/2014 |
| 4/24/2014 | quarterly | $0.20 | 4.05% | 5/1/2014 | 5/5/2014 | 5/15/2014 |
| 1/22/2014 | quarterly | $0.20 | 3.13% | 1/30/2014 | 2/3/2014 | 2/14/2014 |
| 11/7/2013 | quarterly | $0.19 | 3.04% | 11/14/2013 | 11/18/2013 | 11/29/2013 |
| 7/25/2013 | quarterly | $0.19 | 3.13% | 8/1/2013 | 8/5/2013 | 8/15/2013 |
| 4/25/2013 | quarterly | $0.19 | 3.88% | 5/1/2013 | 5/4/2013 | 5/14/2013 |
| 12/4/2012 | quarterly | $0.19 | | | 12/14/2012 | 12/24/2012 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Meridian Bioscience (NASDAQ:VIVO)Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 87.90%
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/2/2017 | Melissa Lueke | CFO | Buy | 4,000 | $12.59 | $50,360.00 | |
| 1/26/2017 | Lawrence Baldini | EVP | Buy | 4,000 | $12.70 | $50,800.00 | |
| 12/2/2016 | Vecheslav A Elagin | EVP | Sell | 7,883 | $17.30 | $136,375.90 | |
| 11/30/2016 | Dwight E Ellingwood | Director | Buy | 1,020 | $17.12 | $17,462.40 | |
| 11/16/2016 | Richard Eberly | EVP | Sell | 4,926 | $17.00 | $83,742.00 | |
| 11/4/2016 | John A Kraeutler | Chairman | Buy | 5,000 | $16.13 | $80,650.00 | |
| 11/3/2016 | Lawrence Baldini | EVP | Buy | 4,900 | $16.00 | $78,400.00 | |
| 8/11/2016 | John Mcilwraith | Director | Buy | 1,000 | $19.57 | $19,570.00 | |
| 4/29/2016 | Catherine Sazdanoff | Director | Buy | 7,700 | $19.20 | $147,840.00 | |
| 12/9/2015 | Vecheslav A Elagin | EVP | Sell | 7,500 | $19.75 | $148,125.00 | |
| 12/1/2015 | Richard Eberly | EVP | Sell | 4,934 | $19.61 | $96,755.74 | |
| 3/2/2015 | Marviette D Johnson | VP | Sell | 1,917 | $19.91 | $38,167.47 | |
| 1/23/2015 | Dwight E Ellingwood | Director | Buy | 1,980 | $17.74 | $35,125.20 | |
| 12/1/2014 | Susan Rolih | EVP | Sell | 11,219 | $16.46 | $184,664.74 | |
| 11/21/2014 | Dwight E Ellingwood | Director | Buy | 1,000 | $16.08 | $16,080.00 | |
| 11/18/2014 | John A Kraeutler | CEO | Sell | 10,500 | $16.20 | $170,100.00 | |
| 11/18/2014 | Melissa Lueke | CFO | Sell | 6,713 | $16.20 | $108,750.60 | |
| 11/11/2014 | David Phillips | Director | Buy | 10,000 | $16.89 | $168,900.00 | |
| 6/13/2014 | Robert J Ready | Director | Sell | 2,700 | $20.03 | $54,081.00 | |
| 12/5/2013 | Vecheslav Elagin | EVP | Sell | 4,141 | $23.74 | $98,307.34 | |
| 11/22/2013 | Susan Rolih | EVP | Sell | 9,086 | $24.18 | $219,699.48 | |
| 11/21/2013 | Richard Eberly | EVP | Sell | 4,926 | $24.50 | $120,687.00 | |
| 11/19/2013 | Lawrence Baldini | VP | Sell | 4,926 | $24.26 | $119,504.76 | |
| 11/11/2013 | John Kraeutler | CEO | Sell | 5,250 | $25.27 | $132,667.50 | |
| 7/26/2013 | Lawrence Baldini | VP | Sell | 32,000 | $24.14 | $772,480.00 | |
| 5/1/2013 | John A Kraeutler | CEO | Buy | 5,000 | $19.63 | $98,150.00 | |
| 12/3/2012 | Lawrence Baldini | VP | Sell | 32,500 | $20.00 | $650,000.00 | |
| 11/13/2012 | Robert J Ready | Director | Sell | 1,800 | $19.46 | $35,028.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Meridian Bioscience (NASDAQ:VIVO)
Latest Headlines for Meridian Bioscience (NASDAQ:VIVO)
| Source: |
|
| Date | Headline |
|---|
 | Meridian Bioscience (VIVO) Presents At UBS Global Healthcare Conference 2017 - Slideshow
seekingalpha.com - May 24 at 8:23 AM |
 | Robbins Arroyo LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of Shareholders
finance.yahoo.com - May 22 at 7:35 PM |
| ETFs with exposure to Meridian Bioscience, Inc. : May 19, 2017
finance.yahoo.com - May 19 at 6:37 PM |
| FDA says Billerica firm’s lead tests may be faulty in some cases
finance.yahoo.com - May 19 at 1:36 PM |
| UPDATE 3-U.S. health officials warn of problems with Meridian lead tests
finance.yahoo.com - May 19 at 1:36 PM |
| Meridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : May 18, 2017
finance.yahoo.com - May 18 at 10:46 AM |
| Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2017 By the Numbers : May 18, 2017
finance.yahoo.com - May 18 at 10:46 AM |
 | Meridian Bioscience (VIVO) Comments on FDA Matter for Subsidiary, Magellan Diagnostics
www.streetinsider.com - May 17 at 9:44 PM |
 | Meridian Bioscience Comments on FDA Matter Involving its Subsidiary, Magellan Diagnostics
www.nasdaq.com - May 17 at 9:44 PM |
 | Tests for lead poisoning may be faulty, US regulators warn
marketbeat.com - May 17 at 6:43 PM |
| Meridian Bioscience stock plummets after FDA warns subsidiary's lead tests may be inaccurate
finance.yahoo.com - May 17 at 10:29 AM |
 | Meridian Bioscience, Inc. (VIVO) Expected to Post Quarterly Sales of $49.41 Million
www.americanbankingnews.com - May 13 at 8:58 AM |
| Zacks: Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Post $0.16 EPS
www.americanbankingnews.com - May 11 at 10:42 AM |
| One of Cincinnati's largest public companies launches CEO search
finance.yahoo.com - May 11 at 3:12 AM |
| Meridian Bioscience, Inc. (VIVO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 10 at 10:36 PM |
| Meridian Bioscience (VIVO) Begins CEO Search as John A. Kraeutler Announces Plans to Retire
www.streetinsider.com - May 10 at 9:57 AM |
| Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire
finance.yahoo.com - May 10 at 9:57 AM |
| Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative on Risks of Lead Exposure for Pregnant Women
finance.yahoo.com - May 9 at 9:45 AM |
| Meridian Continues Its Fight Against Tropical Diseases by Introducing the Most Comprehensive Menu of Antigens and Antibodies for Diagnostic Applications
finance.yahoo.com - May 5 at 3:19 AM |
| Somewhat Positive News Coverage Likely to Affect Meridian Bioscience (VIVO) Stock Price
www.americanbankingnews.com - May 4 at 4:46 PM |
| Canaccord Genuity Reiterates "Hold" Rating for Meridian Bioscience, Inc. (VIVO)
www.americanbankingnews.com - May 3 at 1:33 PM |
| Meridian Bioscience (VIVO) Getting Somewhat Critical Media Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 3:50 PM |
| Brokers Set Expectations for Meridian Bioscience, Inc.'s FY2018 Earnings (VIVO)
www.americanbankingnews.com - May 1 at 1:06 PM |
| Meridian Bioscience, Inc. (VIVO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 1 at 12:56 PM |
| Meridian Bioscience, Inc. (VIVO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 29 at 7:30 AM |
| Somewhat Positive Press Coverage Extremely Likely to Affect Meridian Bioscience (VIVO) Share Price
www.americanbankingnews.com - April 28 at 2:28 PM |
 | Meridian Bioscience Q2 Results Beat View; Reiterates FY17 Outlook
www.rttnews.com - April 27 at 11:01 PM |
| Meridian Bioscience, Inc. (VIVO) Announces $0.13 Quarterly Dividend
www.americanbankingnews.com - April 27 at 8:16 PM |
| Meridian Bioscience, Inc. (VIVO) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - April 27 at 3:16 PM |
| Meridian Bioscience, Inc. (VIVO) Releases FY17 Earnings Guidance
www.americanbankingnews.com - April 27 at 10:36 AM |
| Meridian Bioscience beats 2Q profit forecasts
marketbeat.com - April 27 at 9:34 AM |
| Markets open higher, Street eyes earnings and Trump tax plan - Presented by: The Aol. On Network
www.nasdaq.com - April 26 at 5:06 PM |
| Meridian Bioscience Inc. (Nasdaq: VIVO) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - April 26 at 5:06 PM |
| Meridian Bioscience (VIVO) Receives News Impact Rating of -0.20
www.americanbankingnews.com - April 25 at 12:04 PM |
 | Meridian Bioscience, Inc.: New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
www.finanznachrichten.de - April 25 at 8:49 AM |
| New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
finance.yahoo.com - April 24 at 9:17 AM |
| Somewhat Favorable News Coverage Likely to Impact Meridian Bioscience (VIVO) Stock Price
www.americanbankingnews.com - April 20 at 7:45 PM |
| Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.19 Per Share
www.americanbankingnews.com - April 20 at 2:58 PM |
| Meridian Bioscience, Inc.: ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection
www.finanznachrichten.de - April 18 at 7:40 PM |
| Meridian Bioscience (VIVO) Earning Somewhat Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 17 at 10:53 AM |
| ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection
finance.yahoo.com - April 17 at 8:19 AM |
| Meridian Bioscience, Inc. (VIVO) Receives New Coverage from Analysts at CL King
www.americanbankingnews.com - April 3 at 12:34 PM |
| Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal 2017 Operating Results on Thursday, April 27, 2017
finance.yahoo.com - March 29 at 10:35 AM |
| Coverage initiated on Meridian Bioscience by CL King
finance.yahoo.com - March 28 at 10:32 PM |
| Bioline Launches New JetSeq DNA Quantification Kits
finance.yahoo.com - March 27 at 7:49 PM |
 | Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs Exclusive Partnership to Provide Portable Blood Lead Testing in Africa
us.rd.yahoo.com - March 7 at 8:53 PM |
| MERIDIAN BIOSCIENCE INC Financials
finance.yahoo.com - February 17 at 6:14 AM |
| MERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 10 at 6:29 AM |
| Bioline Launches New JetSeq™ DNA Library Preparation Kits
finance.yahoo.com - February 9 at 6:32 AM |
| Bioline Launches New JetSeq(TM) DNA Library Preparation Kits
finance.yahoo.com - February 9 at 6:32 AM |
Meridian Bioscience (VIVO) Chart for Thursday, May, 25, 2017
